SELLAS Life Sciences Group (SLS) vs Vera Therapeutics (VERA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
SELLAS Life Sciences Group (SLS) has outperformed Vera Therapeutics (VERA) over the past year, gaining 513.2% versus a loss of 2.1%. Over five years, VERA leads with a +99.1% price change compared with +31.9% for SLS. SELLAS Life Sciences Group is the larger company by market cap ($2.35 billion vs $2.15 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SLS | VERA |
|---|---|---|
| Share price | $11.65 | $29.88 |
| Market cap | $2.35B | $2.15B |
| 1-day change | +3.46% | +0.50% |
| YTD return | +209.02% | -41.00% |
| 1-year return | +513.16% | -2.13% |
| 5-year return | +31.94% | +99.07% |
| EPS (TTM) | $-0.21 | $-5.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-26.86M | $-299.62M |
| 52-week high | $15.88 | $56.05 |
| 52-week low | $1.39 | $23.05 |
| Distance from 52-week high | -26.64% | -46.69% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +178.97% | +159.37% |
| Average volume | 6.48M | 2.17M |
| Shares outstanding | 201.95M | 72.06M |
| Employees | 13 | 361 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLS has outperformed VERA by 515.3 percentage points over the past year.
About SELLAS Life Sciences Group
SLS stock →SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel therapeutics for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1, antigen; and SLS009 (tambiciclib), a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
About Vera Therapeutics
VERA stock →Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 361 employees
SLS vs VERA FAQ
Which is bigger, SELLAS Life Sciences Group or Vera Therapeutics?
SELLAS Life Sciences Group (SLS) is larger, with a market capitalization of $2.35B compared with $2.15B for Vera Therapeutics (VERA).
Which stock has performed better over the past year, SLS or VERA?
SLS returned +513.16% over the past 12 months, compared with -2.13% for VERA (price return, excluding dividends). Past performance does not predict future results.
Are SELLAS Life Sciences Group and Vera Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.